Study Evaluating the Safety and Effectiveness of ABT-510 in Subjects With Refractory Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

67

Participants

Timeline

Start Date

April 30, 2003

Conditions
Lymphoma, Non-HodgkinHodgkin's Lymphoma
Interventions
DRUG

ABT-510 - Thrombospondin-1 Mimetic

Trial Locations (14)

12208

Albany Regional Cancer Center, Albany

27511

Raleigh Hematology Oncology Clinic, Cary

32806

Cancer Centers of Florida, P.A., Orlando

33176

Oncology-Hematology Group of South Florida, Miami

33486

The Center for Hematology-Oncology, Boca Raton

38120

The West Cancer Clinic, Memphis

53792

U of W - Comprehensive Care Center, Madison

63142

Arch Medical Services, INC., St Louis

64111

Kansas City Oncology and Hematology Group, Kansas City

77030

MD Anderson Cancer Center, Houston

78229

Hematology Oncology Associates, San Antonio

85012

Hematology Oncology Associates, Phoenix

85712

Arizona Clinical Research Center, Tucson

90033

USC - Norris Cancer Center, Los Angeles

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Abbott

INDUSTRY

NCT00061672 - Study Evaluating the Safety and Effectiveness of ABT-510 in Subjects With Refractory Lymphoma | Biotech Hunter | Biotech Hunter